Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8789957 | Urologic Oncology: Seminars and Original Investigations | 2018 | 7 Pages |
Abstract
Using a large multi-institutional cohort, we were able to demonstrate that FBx outperformed SBx in patients with prior negative systematic biopsy. This was due, in part, to the decreasing CS CDR by SBx with increased number of prior biopsies. The yield of FBx stayed constant and did not decrease with increased number of prior negative biopsies. Therefore, repeat SBx alone in patients with multiple prior negative biopsies will be hindered by lower yield and FBx should be utilized concurrently in these patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Abhinav M.D., Matthew J. D.O., Arvin K. M.D., Ardeshir R. D.O., Srinivas M.D., Soroush M.D., Akhil M.D., Mahir M.D., Jennifer B. M.D., Jeffrey W. M.D., Maria J. M.D., Baris M.D., Peter L. M.D., Bradford J. M.D., Peter A. M.D.,